secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001437749-23-031609
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed completes reverse merger, dosed first patient in Phase 2b DLB trial, Q3 cash $10.4M
--------------------------------------------------------------------------------

- First patient dosed in Phase 2b RewinD-LB study of neflamapimod for dementia with Lewy bodies (DLB).
- Completed reverse merger; now publicly traded on Nasdaq under ticker CRVO.
- Cash and equivalents $10.4M as of Sep 30, 2023; expects cash runway through end of 2024.
- Net income of $2.2M in Q3 2023 vs net loss of $0.9M in Q3 2022, driven by noncash gain from convertible notes conversion.
- Topline primary efficacy data from RewinD-LB study expected in second half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774923031609/0001437749-23-031609-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774923031609/crvo20231113_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031609

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer